RecruitingNCT04912648

FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study


Sponsor

Royal College of Surgeons, Ireland

Enrollment

500 participants

Start Date

Apr 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Androgen excess is the cardinal biochemical feature of polycystic ovary syndrome (PCOS), a lifelong metabolic disorder affecting 10% of women. Serum testosterone correlates with insulin resistance in women, however, there is an urgent need to improve our understanding of the association between androgens and the risk of type 2 diabetes. Recently, a new subclass of androgenic steroids known as 11-oxygenated androgens has been identified. Utilising highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques, our group has recently demonstrated that 11-oxygenated steroids are the predominant androgens in both health controls and women with PCOS, and that these correlate closely with markers of insulin resistance. The bioactive 11-oxygenated androgen 11-ketotestosterone (11KT) binds and activates the androgen receptor with equal affinity to testosterone, yet nothing is known about its impact on metabolism or glucose homeostasis. Intriguingly, unlike testosterone, 11-oxygenated androgens do not decline with age in women, and, therefore, may mediate an increased risk of T2DM in women across their life course. Therefore, this previously ignored androgen class is likely of major importance in female metabolic health, and may represent a novel metabolic risk factor and biomarker. However, 11-oxygenated androgens are not currently measured in routine clinical practice. To date, no population-based or human in vivo physiology studies have examined the association between 11-oxygenated androgens, glucose metabolism and diabetes risk in women, despite the high prevalence of PCOS in the female population. There is emerging evidence, even in women without a confirmed history of PCOS, that the levels of androgens over time correlate with their likelihood of developing metabolic and cardiovascular disease. This has not been studied to date in a prospective manner in healthy women in the background population using long term follow up data.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study — called the FEMAIL study — is investigating the relationship between androgens (male-type hormones, which women also naturally produce) and metabolic health risks in women. It aims to understand how hormones like testosterone affect conditions such as diabetes, heart disease, and weight issues in women across different life stages. You may be eligible if: - You are female and 18 years or older - You are able to provide informed consent You may NOT be eligible if: - You are currently pregnant or breastfeeding - You have significant kidney disease (eGFR <30) or liver impairment - You have a serious health condition such as metastatic cancer or severe cardiorespiratory disease - You have used glucocorticoids (steroids) in the past 6 months - You are taking drugs known to affect steroid or metabolic function within the last 6 months - You have used combined oral hormonal contraceptives in the past 3 months - You participated in another drug study within the past 12 weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLongitudinal follow up

Repeat follow up at 3,5 and 10 years


Locations(1)

Royal College of Surgeons in Ireland

Dublin, Ireland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04912648


Related Trials